Notably, Salirasib and 6H05, two Ras inhibitors, exhibit different mechanisms: Salirasib disrupts Ras signalling to hinder tumour growth, whereas 6H05 selectively targets mutant K‐Ras (G12C) through allosteric inhibition. This evidence concerns the gene KRAS and neoplasm.